Hostname: page-component-7b7567c8c-fvjsw Total loading time: 0 Render date: 2026-11-17T08:40:51.249Z Has data issue: false hasContentIssue false

Methicillin-Resistant Staphylococcus aureus: Clinical and Laboratory Features

Published online by Cambridge University Press:  02 January 2015

Kenneth E. Aldridge*
Affiliation:
Departments of Medicine, Pathology, and Obstetrics and Gynecology, Louisiana State University Medical Center, New Orleans, Louisiana
*
Pathology, Obstetrics and Gynecology, LSU Medical Center, New Orleans, LA 70112

Extract

Not long after the introduction of penicillin G for anti-staphylococcal therapy, penicillin G resistant strains of staphylococci were isolated and were found to produce penicillinase enzymes. In 1959 methicillin, a penicillinase resistant penicillin (PRP), was introduced in England for therapy of these strains. Within 2 years the first strains of methicillin-resistant Staphylococcus aureus (MRSA) were reported in that country. Subsequently, reports of MRSA infections throughout Europe appeared. Reports from Switzerland and Denmark indicated that 30% to 50% of all nosocomial S. aureus isolates and 40% of all S. aureus bacteremia isolates, respectively, were due to MRSA. Although sporadic reports of MRSA infections appeared in the US after 1960 the first documented outbreak of MRSA infections occurred at Boston City Hospital in 1968. Even today there is not a complete understanding of MRSA and its role in infectious diseases, however, a vast amount of information has accumulated and certain aspects of this information will be discussed.

Information

Type
Special Sections
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1985

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable